TAS-102 Completed Phase 3 Trials for Refractory Metastatic Gastric Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02500043Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer